Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for cancers. Its lead product candidate is UV1, a peptide-based vaccine that induces T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.
KI-Analyse von ULTIMOVACS AS DK1
Wähle eine Analyse aus und der finAgent liefert dir tiefgehende Einblicke dazu!
Neuste KI Analysen zu ULTIMOVACS AS DK1
Für dieses Unternehmen sind noch keine KI-Threads verfügbar.